Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CUPR
vs
S&P 500
S&P 500
Over the past 12 months, CUPR has underperformed S&P 500, delivering a return of -75% compared to S&P 500's +16% growth.
Stocks Performance
CUPR vs S&P 500
Performance Gap
CUPR vs S&P 500
Performance By Year
CUPR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cuprina Holdings (Cayman) Ltd
Glance View
Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 14 full-time employees The company went IPO on 2025-04-10. The firm is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sectors. The firm manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy (MDT), which is an alternative to surgical debridement. The company also offers two lines of chronic wound care products in its pipeline. Such lines of pipeline chronic wound care products include Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus), and Products utilizing medical leeches for wound treatment.